1116433-11-4

1116433-11-4 structure

Name: Itolizumab
Chemical Name: Itolizumab
CAS Number: 1116433-11-4
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Infection
Create Date: 2023-01-15 21:27:02
Modify Date: 2024-09-15 23:06:23
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].

Name	Itolizumab

Description	Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
Target	CD6[1]
In Vitro	Itolizumab (100 μg/mL) inhibits T cell proliferation[4]. Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs[4]. Itolizumab (40 μg/mL) reduces CD26hiCD161+ CD8+ T cells during culture of PBMCs overnight[5]. Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions[6].
In Vivo	Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)[7]. Animal Model: Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)[7] Dosage: 60 μg or 300μg Administration: Intraperitoneal injection (i.p.), prior to PBMC transplantation. Result: Decreased mortality compared to the vehicle (100% vs. 10%).
References	[1]. Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. [2]. Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. [3]. Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. [4]. Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. [5]. Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688. [6]. Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088. [7]. Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603.

No Any Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2228208-29-3	2228213-19-0
2248360-72-5	2248277-50-9
2248379-01-1	2248359-67-1
2248391-07-1	2248415-43-0
2248380-42-7	2248351-65-5